semaglutide mash label expansion adds few new candidates Semaglutide, a GLP-1R agonist, is

Y., Chan, R

For growth hormone secretagogues, this typically includes IGF-1 (insulin-like growth factor 1), a comprehensive metabolic panel, fasting glucose, HbA1c, and a lipid panel

Balanced Bodies in Action, Stories of Success So thankful to have found this facility

Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500

Palomas specialized care in thyroid health can help determine whether GLP-1 medications are appropriate for you